Portfolio overlap

OZEM / PPH

Overlap	Shared positions
26.40%	4

Roundhill GLP-1 & Weight Loss ETF

Report dates 06/30/2026 | 99.59% NAV

Overlap / OZEM 35.87%

VanEck Pharmaceutical ETF

Report dates 06/30/2026 | 99.51% NAV

Overlap / PPH 34.44%

Largest shared positions

Security	OZEM	PPH	Overlap
Eli Lilly & Co	12.69%	20.23%	12.69%
Novo Nordisk A/S	12.96%	5.37%	5.37%
Pfizer Inc	6.38%	4.51%	4.51%

Weights are percentages of each fund's net assets. Shared weight is the sum of the smallest weight per matched common-stock class. Unmatched positions are excluded without renormalizing the weights.

History





9 matched portfolio dates from 06/30/2024 to 06/30/2026. Both filings use the same portfolio date. The minimum matched share of net assets is 99.17%. The filing dates are 50–60 days after the portfolio dates. This is filing lag. The archive does not establish an exact intraday release time.

Largest changes

03/31/2026 / 06/30/2026 -3.50 pp

Security	Overlap 03/31/2026	Overlap 06/30/2026	Change (pp)
Eli Lilly & Co	16.10%	12.69%	-3.41
Pfizer Inc	5.23%	4.51%	-0.72
Novo Nordisk A/S	4.81%	5.37%	+0.56
AstraZeneca PLC	3.76%	3.83%	+0.07
All other shared classes			0.00

Sources and methodology

Weights are percentages of each fund's net assets. Shared weight is the sum of the smallest weight per matched common-stock class. Unmatched positions are excluded without renormalizing the weights.

nport-common-equity-v1

Report dates	Weight (%)	Classes	OZEM · SEC	PPH · SEC
06/30/2026	26.40%	4	0000894189-26-023641	0001410368-26-086926
03/31/2026	29.90%	4	0000894189-26-015396	0001410368-26-054845
12/31/2025	29.66%	4	0000894189-26-006092	0001410368-26-020317
09/30/2025	30.32%	4	0000894189-25-015255	0001410368-25-028384
06/30/2025	31.42%	4	0001145549-25-055414	0001752724-25-196060
03/31/2025	27.44%	5	0001145549-25-034559	0001752724-25-119468
12/31/2024	30.34%	5	0001145549-25-014788	0001752724-25-041011
09/30/2024	30.42%	5	0001145549-24-071948	0001752724-24-256561
06/30/2024	30.38%	5	0001145549-24-054808	0001752724-24-183494